IMP3 and prostate cancer: Szarvas et al. [15] found that IMP3, a member of IMP family was positively expressed in 15% (15/101) of clinically localized prostate cancer tissues and 65% (15/23) of palliatively treated metastatic prostate cancer tissues, whereas was not detected in the benign prostate hyperplasia tissues.